Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Modality
unclassified
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07424404CT.gov A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively | — | Recruiting | — | — | — |
NCT07288567CT.gov A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN) | — | Recruiting | — | — | — |
NCT07061288CT.gov A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT | — | Recruiting | — | — | — |
NCT06882785CT.gov A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia | — | Recruiting | — | — | — |
NCT06572449CT.gov Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Karxt (this asset) | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | P3 | B · 59 |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Roluperidone | Minerva Neurosciences | P3 | BBB |
| Iloperidone | Vanda Pharmaceuticals | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Karxt
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P3 | B · 60 |
| Autism Spectrum Disorder | — | P3 | B · 60 |
| Psychotic Disorder | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Karxt in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/karxt-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →